Adaptive Radiotherapy in Non-small Cell Lung Cancer (NSCLC)
Primary Purpose
Non-small Cell Lung Cancer
Status
Completed
Phase
Phase 2
Locations
Netherlands
Study Type
Interventional
Intervention
Radiotherapy and concurrent chemo-therapy
Sponsored by
About this trial
This is an interventional treatment trial for Non-small Cell Lung Cancer focused on measuring Radiotherapy, NSCLC, Stage II-III non-small cell lung cancer
Eligibility Criteria
Inclusion Criteria:
- Histological or cytological proven NSCLC
- UICC stage I-III, or solitary metastases (<6), which are amendable for radical local treatment
- Performance status 0-2
- IMRT technique
Exclusion Criteria:
- Not NSCLC of mixed NSCLC and other histologies (e.g. small cell carcinoma)
- Stage IV, except for solitary (<6) metastases
- Performance status 3 or more
Sites / Locations
- MAASTRO clinic
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Radiotherapy
Arm Description
Outcomes
Primary Outcome Measures
Proportion of patients able to receive 69Gy as TTD
Secondary Outcome Measures
Overall survival
Progression free survival
Dyspnea (CTCAE 4.0)
Dysphagia (CTCAE 4.0)
Patterns of recurrence
Full Information
NCT ID
NCT01207063
First Posted
July 26, 2010
Last Updated
August 16, 2018
Sponsor
Maastricht Radiation Oncology
1. Study Identification
Unique Protocol Identification Number
NCT01207063
Brief Title
Adaptive Radiotherapy in Non-small Cell Lung Cancer (NSCLC)
Official Title
Adaptive Radiotherapy for Stage II-III Non-small Cell Lung Cancer
Study Type
Interventional
2. Study Status
Record Verification Date
August 2018
Overall Recruitment Status
Completed
Study Start Date
March 2011 (Actual)
Primary Completion Date
August 2018 (Actual)
Study Completion Date
August 2018 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Maastricht Radiation Oncology
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The investigators group uses an individualised radiation dose approach in which the dose is escalated up to pre-defined tissue constraints (see below). The target dose to the tumor is 69Gy. However, this dose cannot be reached in approximately 30% of the patients, even with an IMRT (Intensity Modulated Radiotherapy) technique, because the MLD (Mean Lung Dose) constraint of 20Gy is reached at a TTD (Total Treatment Dose) below 69Gy. In this study, the investigators will adapt the treatment by performing a new (PET)-CT at day 12 during radiotherapy and in case of a decreased Planning Target Volume (PTV), the dose mey be increased.
Detailed Description
Eligible patients will receive concurrent chemo-radiotherapy to the primary tumor and the initially involved mediastinal lymph nodes to an MLD (Mean Lung Dose) of 20 +/- 1Gy, irrespective of lung function.
Other dose constraints: spinal cord max: 54Gy, brachial plexus (Dmax):66Gy.
In concurrent with chemotherapy, radiotherapy will be delivered as follows:
First three weeks /30 fractions:twice-daily fractions of 1.5Gy, with 8h to 10h as interfraction interval, 5 days per week. Total dose: 45Gy/30 fractions.
Thereafter: once-daily fractions of 2.0Gy, 5 days per week until the target dose has been reached.
In sequential or radiotherapy alone schedules, twice-daily 1.8Gy with an interfraction interval of at least 8h will be delivered.
The radiation doses will be specified according to ICRU 50. Lung density corrections will be applied, as well as all standard QA procedures. Technical requirements are the same as in standard practice at MAASTRO clinic.
Chemotherapy schedules allowed:
1-2 cycles induction chemotherapy: any third generation schedule is allowed. The type will be registered.
Concurrent part: (day 1=first day of radiotherapy)
cisplatin-vinorelbine
cisplatin-docetaxel
cisplatin-etoposide
cisplatin-pemetrexed in non-squamous histologies
Q3 week; 3 cycles
When the calculated creatinin clearance is less than 60 ml/min, cisplatin may be substituted for carboplatin.
In case the TTD(Total Treatment Dose)=69Gy cannot be reached because of a limiting MLD, a FDG-PET-CT will be performed at day 12 during radiotherapy. GTV's (Gross Tmor Volume), CTV's (Clinical Target Volume) and PTV's (Planning Target Volume) will be delineated and a new plan calculated. The endpoint will be the proportion of patients that will receive 69Gy.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Non-small Cell Lung Cancer
Keywords
Radiotherapy, NSCLC, Stage II-III non-small cell lung cancer
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
40 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Radiotherapy
Arm Type
Experimental
Intervention Type
Other
Intervention Name(s)
Radiotherapy and concurrent chemo-therapy
Intervention Description
Radiotherapy and concurrent chemo-therapy
Primary Outcome Measure Information:
Title
Proportion of patients able to receive 69Gy as TTD
Time Frame
3 months
Secondary Outcome Measure Information:
Title
Overall survival
Time Frame
3 months
Title
Progression free survival
Time Frame
3 months
Title
Dyspnea (CTCAE 4.0)
Time Frame
3 months
Title
Dysphagia (CTCAE 4.0)
Time Frame
3 months
Title
Patterns of recurrence
Time Frame
3 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Histological or cytological proven NSCLC
UICC stage I-III, or solitary metastases (<6), which are amendable for radical local treatment
Performance status 0-2
IMRT technique
Exclusion Criteria:
Not NSCLC of mixed NSCLC and other histologies (e.g. small cell carcinoma)
Stage IV, except for solitary (<6) metastases
Performance status 3 or more
Facility Information:
Facility Name
MAASTRO clinic
City
Maastricht
State/Province
Limburg
ZIP/Postal Code
6229 ET
Country
Netherlands
12. IPD Sharing Statement
Learn more about this trial
Adaptive Radiotherapy in Non-small Cell Lung Cancer (NSCLC)
We'll reach out to this number within 24 hrs